Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 26;9(8):e003132. doi: 10.1136/jitc-2021-003132

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Neoantigen-targeted personalized SVMAV preparation and its antitumor effect verification. (A) Workflow of the neoantigen-targeted personalized SVMAV. (B) Prediction of three neoantigens by exome sequencing of Hepa 1–6 cells. (C) Schematic of the HLS@SVMAV preparation. (D) Treatment scheme in the orthotopic HCC mouse model. (E) Photograph of mouse livers from different groups (n=5). (F) Quantification of tumor area by pixel counting. (G) Representative multiplex fluorescent IHC staining images of orthotopic HCC tissues. CD8a, green; F4/80, magenta; CD86, yellow; PD-L1, red; DAPI, blue. white scale bar represents 20 µm. Dashed circles delimit the F4/80⁺CD86⁺ M1 macrophages. aPD-1, antiprogrammed cell death protein 1; COI, cellular orthotopic injection; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; SVMAV, Self-assembling Vehicle-free Multi-component Antitumor nanoVaccine.